MIRLET7B and MIRLET7A3 host geneGenealiases: PRR34-AS1 · linc-Ppara
Q-omics provides the consensus-scored MIRLET7BHG profile across patient tissues and cancer cell-line models. MIRLET7BHG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIRLET7BHG is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MIRLET7BHG RNA expression shows 15,465 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where MIRLET7BHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIRLET7BHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIRLET7BHG survival associations across molecular data types. MIRLET7BHG RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIRLET7BHG RNA expression–survival associations across cancer types. High MIRLET7BHG expression shows unfavorable associations in UVM, KIRC, OV, CESC and LAML, but favorable associations in ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIRLET7BHG RNA expression.
This table summarizes MIRLET7BHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIRLET7BHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIRLET7BHG shows lower tumor expression in KIRP, KICH and BRCA and higher tumor expression in COAD, LIHC and CHOL. The COAD box plot shows higher MIRLET7BHG RNA expression in tumor versus normal tissue (log2 FC = +0.573, t-test p < 0.001).
This table shows molecular features associated with MIRLET7BHG in patient tissues and cancer cell lines. In patient samples, MIRLET7BHG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
